Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.51 |
| ▸ | KIT | P10721 | 12/20 | 0.49 |
| ▸ | BRAF | P15056 | 12/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.41 |
| ▸ | VNN1 | O95497 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6542947 | 0.93 | JAK3 (0.59) | JAK3IRAK4KITBRAFVNN1 | |
| SCHEMBL4034696 | 0.92 | JAK3 (0.47) | JAK3IRAK4KITBRAFTRPV1 | |
| SCHEMBL4034820 | 0.88 | JAK3 (0.46) | JAK3IRAK4KITBRAFTRPV1 | |
| SCHEMBL4042030 | 0.87 | JAK3 (0.47) | JAK3IRAK4KITBRAFFLT1 | |
| SCHEMBL4034859 | 0.85 | IRAK4 (0.56) | JAK3IRAK4KITBRAFFLT1 | |
| SCHEMBL4034704 | 0.84 | JAK3 (0.46) | JAK3IRAK4KITBRAFTRPV1 | |
| SCHEMBL4042743 | 0.81 | KIT (0.53) | KITBRAF | |
| SCHEMBL6792344 | 0.81 | RXFP1 (0.42) | JAK3IRAK4KITBRAFTRPV1 | |
| SCHEMBL6543366 | 0.81 | KIT (0.64) | JAK3IRAK4KITBRAF | |
| SCHEMBL4032722 | 0.80 | KIT (0.50) | KITBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040254185-A1 | Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254185-A1 | Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 | FLT4, KDR, FLT1 | JAK3 33/4885IRAK4 159/4885KIT 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.